bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P6-11-15: Pre-clinical investigation of estrogen receptor β agonists for the treatment of breast cancer
Authors: Samayoa C , Krishnegowda NK , Vadlamudi RK , Tekmal RR 
Published: March 2017

Abstract
Breast Cancer is the primary cause of cancer-associated mortality worldwide, and in United States alone, more than 250,000 women are diagnosed every year. Current breast cancer treatment strategies focus on Estrogen Receptor α signaling, given that the majority of cases diagnosed are ERα positive. These treatment strategies include endocrine therapies; such as anti-estrogens or aromatase inhibitors. Although, endocrine therapy has been demonstrated to be successful and effective, therapy resistance commonly arises and results in relapse. While current endocrine therapies focus on ERα signaling, emerging studies highlight the importance of Estrogen Receptor β.Unlike ERα, ERβ has been shown to have tumor-suppressive function in various cancers, including breast cancer. Recent studies have identified, synthesized, and tested the clinical safety of ERβ-selective agonists. The objective of this study was to investigate the utility of using ERβ agonists in the treatment of breast cancer.
To investigate the utility of ERβ agonists in the treatment of breast cancer, we used in-vitro and in-vivo pre-clinical models systems. Our results demonstrated that treatment with ERβ agonists, S-Equol and LY500307, was able to inhibit the short-term and long-term growth of both endocrine therapy sensitive and resistant breast cancer cells. Progression through the cell cycle, cell migration and cell invasion was also abrogated upon treatment. In-vivo, our syngeneic tumor mouse model demonstrates a decline in tumor growth rate after treating with a combination of letrozole and ERβ agonist. Gene expression array analysis reveal that treatment with ERβ agonist elicits changes in key signaling molecules involved in cell death and cell cycle pathways. In Letrozole resistant cells, Letrozole treatment had not effect on gene expression, while LY500307 treatment resulted in the modulation of 780 genes. Interestingly, combining Letrozole with LY500307 resulted in the modulation of 966 genes, of which 417 were unique to the combination treatment. Our studies suggest that activation of ERβ signaling is a valuable strategy in the treatment of breast cancer, even in cases which have developed resistance to current endocrine therapies.
Citation Format: Samayoa C, Krishnegowda NK, Vadlamudi RK, Tekmal RR. Pre-clinical investigation of estrogen receptor β agonists for the treatment of breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-11-15.
Abstract P6-12-16: Delivery and anti-tumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) in metastatic xenograft models of triple negative breast cancer
Authors: Lee H , Ventura M , Bernards N , Mohammad AS , Foltz W , Fitzgerald J , Jaffray DA , Lockman PR , Zheng J , Hendriks BS 
Published: March 2017

Abstract
This abstract was not presented at the symposium.
Abstract P6-16-07: Analysing the factors affecting survival of breast cancer patients with leptomeningeal metastasis
Authors: Niwinska A , Rudnicka H , Kunkiel M , Jagiello-Gruszfeld A , Nowecki Z 
Published: March 2017

Abstract
AIM: To assess those factors which affect survival in three groups of breast cancer patients with leptomieningeal metastasis (LM) treated at the Warsaw Cancer Center in Poland. Subject groups were: 187 patients consecutively referred during 2003-2015 (group A), 69 patients with LM as the first/only site of dissemination of the disease (group B) and 27 patients who survived for more than 1 year (group C).
Methods: Univariate and Cox multivariate analysis were performed using the following variables: age, Karnofsky Performance Status (KPS), biological subtype of breast cancer (ER/PR+HER2- vs. HER2+ vs. ER-PR-HER2-), systemic intravenous/oral treatment, intrathecal treatment, radiation therapy and the number of treatment methods.
Results. Median survival of patients in group A was 17 weeks, in group B 18 weeks (p=0.72) and in group C 19.2 months. In group A, factors positively affecting survival were: KPS =&gt; (p=0.01), older age (p=0.003), biological subtype ER/PR+HER2- (p=0.003), systemic intravenous/oral treatment (p=0.0001), intrathecal treatment (p=0.001) and radiation therapy (p=0.001). In the group B, the most important factors affecting survival were a KPS=&gt; 70 (p=0.001), biological subtype ER/PR+HER2- (p=0.04), systemic therapy (p=0.001) and intrathecal therapy (p=0.001). For group C, older patients (p=0.01) with ER/PR+HER2- breast cancer (p=0.05, HR 0.18) and after systemic intravenous/oral treatment (p=0.02) had higher a probability of survival after 1 year.
Conclusions: Those breast cancer LM patients who were older, having high KPS, with luminal breast cancer and treated with systemic inravenous/oral therapy had a higher probability of survival than the rest of the group. Based on the presented data, the role of intrathecal therapy could not be exactly defined.
Citation Format: Niwinska A, Rudnicka H, Kunkiel M, Jagiello-Gruszfeld A, Nowecki Z. Analysing the factors affecting survival of breast cancer patients with leptomeningeal metastasis [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-16-07.
Abstract PD7-06: SEER study of breast cancer-specific mortality in patients with poorly differentiated tumors treated based on recurrence score results
Authors: Petkov VI , Miller DP , Howlader N , Baehner FL , Penberthy L , Shak S 
Published: March 2017

Abstract
Introduction: The SEER Program of the NCI is an authoritative source of cancer incidence and survival statistics. Linking the 21-gene assay Recurrence Score® (RS) results to the SEER Registries (N=44,825) demonstrated very low 5-year breast cancer-specific mortality (BCSM) with RS &lt;18 across many key clinical-pathological subgroups, such as age, nodal status, tumor grade, and size (npj Breast Cancer. 2016;2:16017). Given the large sample size and specific interest in outcomes as a function of tumor grade, further stratification of patients with poorly differentiated tumors was performed to determine BCSM when examined by both tumor grade and tumor size.
Methods: Patients were eligible if node negative (N0), HR+, HER2-negative (by RT-PCR), had no prior malignancy, had poorly differentiated (G3) tumors, and were diagnosed between Jan 2004 (test available in Jan 2004) and Dec 2011 (SEER survival updated through 2012). BCSM was defined according to pre-existing robust methodology (J Natl Cancer Inst. 2010;102:1584). RS was categorized according to the cutpoints of 18 and 31 established in the NSABP B-14 study. Five-year BCSM was estimated using actuarial methods.
Results: Among 6,666 eligible patients with G3 tumors, 4,683 had tumors ≤2 cm and 1,983 had tumors &gt;2 cm. Median age was 57 years; 99.1% were female. Median follow-up was 39 months. The proportion of patients with RS &lt;18 was 29% among those with tumors ≤2 cm and 25% among those with tumors &gt;2 cm, somewhat lower than the overall population. For RS &lt;18, 5-year BCSM was 0.3% (G3; ≤2 cm) and 1.4% (G3; &gt;2 cm); reported chemotherapy use was 10% and 16%, respectively. 5-year BCSM for all groups are provided in Table. An additional year of BCSM follow-up in N0 G3 disease, as well as results for patients with node positive (micrometastases or 1-3 positive nodes) G3 disease, will be available for presentation.
N0, G3 tumor, RS &lt;18N0, G3 tumor, RS 18-30N0, G3 tumor, RS ≥31Tumor sizeN5-y BCSM (95% CI)N5-y BCSM (95% CI)N5-y BCSM (95% CI)≤2 cm13620.3% (0.1%, 1.2%)21482.1% (1.3%, 3.3%)11732.9% (1.8%, 4.7%)&gt;2 cm4861.4% (0.4%, 4.6%)8514.6% (2.7%, 7.8%)6469.0% (6.0%, 13.4%)
Conclusions: Although patients with poorly differentiated tumors have worse prognosis in general, the RS identifies a sizable proportion of patients who can expect good outcomes without chemotherapy and its associated toxicity.
Citation Format: Petkov VI, Miller DP, Howlader N, Baehner FL, Penberthy L, Shak S. SEER study of breast cancer-specific mortality in patients with poorly differentiated tumors treated based on recurrence score results [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD7-06.
Abstract A27: Evaluation of two HPV vaccination educational interventions for Hispanic parents
Authors: Fernandez Maria E. , Savas Lara , Angelica Roncancio , Khan Myrna , Fernandez-Espada Natalie , Rodriguez Serena , Vernon Sally 
Published: March 2017

Abstract
Background:
We examined effectiveness of two lay health worker-delivered educational interventions for parents to increase HPV vaccination among Hispanic girls.
Methods:
Twenty-nine clinics were randomized to standard care or one of two interventions: a print fotonovela or an tailored interactive multimedia intervention (TIMI). Lay health workers delivered the interventions to parents. Data collectors completed follow-up assessments at 6 and 12 months. We assessed vaccine initiation at first follow-up and series completion by end of the study. Data were analyze using hierarchical logistic regression.
Results:
Among all participants recruited at baseline (576= fotonovela intervention group; 389=TIMI intervention group; 433=control group) intent-to-treat analysis indicated significant differences in vaccine initiation between TIMI and control at 6-month follow-up (OR: 1.63, 95% CI: 1.13-2.35, p=0.01), and between fotonovela and control (OR: 1.67, 95% CI: 1.20-2.32, p=0.002). Per protocol analyses (including only parents who completed follow-up surveys or whose daughter's vaccination status was ascertained through medical records) showed significant differences in initiation at 6 month follow-up: between TIMI and control (OR: 1.79, 95% CI: 1.21-2.70, p=0.004) and between fotonovela and control (OR: 1.65, 95% CI: 1.17-2.34, p=0.004). There were no statistically significant differences between TIMI and fotonovela (OR: 1.08 CI: 0.76-1.55, p=0.66).
Conclusion:
Hispanic parents receiving education - either the fotonovela or the TIMI - were more likely to initiate HPV vaccination within 6 months than parents in the comparison group. We will determine education effectiveness on completion of the 3-dose HPV series at 12-month follow-up.
Citation Format: Maria E. Fernandez, Lara Savas, Roncancio Angelica, Myrna Khan, Natalie Fernandez-Espada, Serena Rodriguez, Sally Vernon. Evaluation of two HPV vaccination educational interventions for Hispanic parents. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr A27.
Abstract A40: Capital Breast Care Center: A Patient Navigation Exemplar
Authors: Wallington Sherrie Flynt , Oppong Bridget , Dash Chiranjeev , Coleman Tesha , Greenwald Holly , Torres Tanya , Iddirisu Marquita , Adams-Campbell Lucile 
Published: March 2017

Abstract
Introduction. Breast cancer is the second leading cause of cancer deaths for American women. Washington, DC, has one of the highest incidence and mortality rates for breast cancer in the U.S. Patient navigation coupled with informational and community resources are important strategies that assist patients' access and help them understand the complex world of cancer care.
Aims.The Georgetown Lombardi Comprehensive Cancer Center's Capital Breast Care Center (CBCC) serves as an exemplary community-embedded facility that develops multiple intra community partnerships to improve patient access to health care. The aim of this study is to detail the role of patient navigation at the Capital Breast Care Center, with an emphasis on community engagement and community-based partnerships.
Program process description. We describe the development and application of the CBCC patient navigation process and navigation components: (a) creating partnerships; (b) educating members of the community about mammograms; (c) providing patient navigation into screening assistance; and (d) helping women with coordination of diagnostic follow-up. Data were collected from 2004-2015 and analyzed in 2015.
Program process evaluation results. CBCC established 41 community partnerships categorized by different organizational types that include transitional housing facilities, health service providers, neighborhood associations, churches, senior centers, and local neighborhood recreation centers. Application of the CBCC navigation model yielded important lessons; in general, partnerships and patient navigation.
Discussion. Partnerships, community engagement, and informational resources are all crucial to the patient navigation process in providing access to quality care for all patients.
Citation Format: Sherrie Flynt Wallington, Bridget Oppong, Chiranjeev Dash, Tesha Coleman, Holly Greenwald, Tanya Torres, Marquita Iddirisu, Lucile Adams-Campbell. Capital Breast Care Center: A Patient Navigation Exemplar. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr A40.
Abstract A44: Tobacco education sessions as a recruitment tool for a culturally tailored smoking cessation program for American Indians: All Nations Breath of Life
Authors: Goeckner Ryan , Gunville Jordyn , Smith T Edward , Nazir Niaman , Daley Sean M. , Choi Won , Daley Christine 
Published: March 2017

Abstract
American Indians have the highest smoking rates and lowest quit rates of any racial/ethnic group in the US. Researchers and community members from the American Indian Health Research and Education Alliance (AIHREA) created and tested a culturally-tailored smoking cessation program, All Nations Breath of Life (ANBL). ANBL is designed to help American Indians quit smoking while respecting the sacred nature of tobacco. To increase enrollment in ANBL, American Indian smokers were approached at cultural events and asked to attend a 30-minute educational session (in-person, n = 179; televideo, n = 97). The educational sessions were developed using the Health Belief Model as a framework and focused on smoking facts and American Indian health. In pre- and post-tests, participants in both sessions demonstrated increased motivation and confidence to quit smoking. Approximately 9% of in-person session participants and 30% of televideo participants were recruited into ANBL. The results indicate that education sessions are an excellent way to educate American Indians about smoking, its related outcomes, and American Indian health. More importantly, these sessions were a successful recruitment tool for ANBL. In conclusion, hosting informational sessions at cultural events about smoking are an effective way to recruit people into a smoking cessation program.
Citation Format: Ryan Goeckner, Jordyn Gunville, T Edward Smith, Niaman Nazir, Sean M. Daley, Won Choi, Christine Daley. Tobacco education sessions as a recruitment tool for a culturally tailored smoking cessation program for American Indians: All Nations Breath of Life. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr A44.
Abstract A59: Influence of Spirituality on Cancer Risk Assessment Decisions: Perspectives of Hispanic & non-Hispanic Women
Authors: Vicuna Belinda 
Published: March 2017

Abstract
Spirituality has been a prominent coping resource among those facing cancer and can be especially relevant in dealing with the uncertainty of cancer risk. As part of a larger study, the aim of this study was to explore how spirituality influences decisions to get cancer risk assessment among Hispanic and non-Hispanic women in New Mexico. A total of 16 women with a personal history of breast and ovarian cancer participated in focus group or an interview. Ethnically, 50% of participants identified as Hispanic and racially, 69% identified as White. The mean age was 56 years old, 63% had a college degree, and 69% had a yearly household income of &lt; $50,000. A majority (81%) of women stated that their spirituality was important or highly important in their lives. Although 94% replied that their spirituality does not influence their decisions to get genetic testing, discussion of spirituality within the context of getting cancer risk assessment was especially relevant among Hispanic participants. Qualitative analyses were done to extract themes on how spirituality might act as a facilitator or barrier to engaging in cancer risk assessment. Among non-Hispanic participants, there was acknowledgement of how spirituality may impact others' decision and a strong sentiment that spirituality not was relevant in their personal decisions for genetic testing. Among English-speaking Hispanic participants, there was a strong emphasis on the role that spirituality plays in well-being and as a central role in New Mexican Hispanic culture. Among Spanish-Speaking Hispanic participants, spirituality was paramount in coping with the experience of breast cancer and in encouraging genetic testing and screening as an avenue to protect health for individual and the family. In conclusion, spirituality may not have a direct influence on decisions to seek genetic testing for cancer risk, but the indirect influence of spirituality through culture and as a coping resource does vary by ethnicity.
Citation Format: Belinda Vicuna. Influence of Spirituality on Cancer Risk Assessment Decisions: Perspectives of Hispanic & non-Hispanic Women. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr A59.
Abstract B01: Designing a feasible breast cancer genetics research study: Lessons learned
Authors: Bauza Colleen , Fordxs Marvella E. 
Published: March 2017

Abstract
Background: The current trend toward personalized medicine in cancer care relies heavily on cancer genetics research (CGR). However, members of diverse populations are significantly less likely than others to participate in CGR. Therefore, CGR results lack generalizability to these groups. This study tests strategies to recruit European American (EA) and African American (AA) women of varied income levels who are at risk of developing breast cancer (BC) to CGR.
Design: Recruitment began in January 2015 and ended in May 2015. Study flyers are strategically placed in the BC screening clinics at a National Cancer Institute-designated cancer center. Interested patients call the study coordinator for eligibility screening. To supplement low accrual rates using this method, in June 2015, the investigators began using the EPIC electronic health record to identify BC-screened patients who potentially met study eligibility criteria. EPIC-identified patients are randomly selected in groups of 50 and are sent a letter describing the study; if interested, they then call the study coordinator for eligibility screening.
Results: The original recruitment strategy resulted in 11 participants (7 AA, 4 EA) while 21 participants (10 AA, 11 EA) were recruited using the EPIC approach.
Discussion: The EPIC recruitment strategy resulted in a higher number of recruited participants than the study flyer strategy. Identifying effective approaches to recruit diverse populations to CGR is critically important. Study results show that using a targeted recruitment approach such as the pre-screening approach in the EPIC strategy can bolster participation of diverse populations in CGR.
Citation Format: Colleen Bauza, Marvella E. Fordxs. Designing a feasible breast cancer genetics research study: Lessons learned. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr B01.
Abstract B21: Functional Role of ETS/ETV1-Fusion Proteins in Prostate Cancer and Other Cancers
Authors: Morsalin Sharif , Yang Chunshu , Fang Jinbo , Fujimura Yasuo , Kayarthodi Shubhalaxmi , Xu Huali , Gunnal Ujwala , Clark Clarence , Menter Julian , Rao Veena , Reddy Shyam 
Published: March 2017

Abstract
After lung cancer prostate cancer is the most common age related cancer among men in the United State. African American men have the highest incidence of, and mortality rate from, this disease in the United States (American Cancer Society). According to the American Cancer Society, 29% of all cancer cases and 9% of all cancer deaths are a result of prostate cancer. By the age of 75, one out of nine men will develop prostate cancer. Individuals who are at higher risk include African-American men, men over 60 years of age and those with a family history of the disease. African-Americans also have twice the risk of developing prostate cancer as Caucasians. E26 transforming sequence (ETS) factors play an important role in cancers. ETV1, an ETS factor, is notable for its association in prostate cancers, where truncated ETV1 (dETV1) or its full length counterpart is overexpressed in approximately 10% of the patients. Formation of cancers may be brought on by deregulation of Wnt/β-catenin pathway. Mutations that stabilize β-catenin may contribute to loss of cell growth control in tumorigenesis. ETV1's interaction with components of the Wnt/β-catenin pathway may alter β-catenin interaction with downstream tumor suppressor genes, which are critical in regulating apoptosis and cell growth properties. Our results show that ETV1 regulates Wnt/β-catenin activity. We provide evidence that ETV1 activates kinases that regulate Wnt/β-catenin activity by post translational modification. Also, we demonstrate that therapeutic agents that reverse ETV1-regulated Wnt/β-catenin activity can be used to target ETV1-positive prostate cancer cells. These therapeutic agents will have a profound impact on prevention and treatment of prostate cancer and this may help to reduce health disparity seen in the minority patients.
Citation Format: Sharif Morsalin, Chunshu Yang, Jinbo Fang, Yasuo Fujimura, Shubhalaxmi Kayarthodi, Huali Xu, Ujwala Gunnal, Clarence Clark, Julian Menter, Veena Rao, Shyam Reddy. Functional Role of ETS/ETV1-Fusion Proteins in Prostate Cancer and Other Cancers. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr B21.